DEF: BioLife Solutions Reports Strong 2024 Financials and Strategic Realignment, Outperforming Peer Group TSR

Sentiment:

Proxy Statement 8 July 2025 4:58 PM

BioLife Solutions, Inc. announced robust 2024 financial results, including significant revenue growth and positive adjusted EBITDA, driven by strategic divestitures and a sharpened focus on the cell and gene therapy market, while also detailing executive compensation and corporate governance updates ahead of its 2025 Annual Meeting.

Better than expectedRevenue for 2024 reached $82.3 million, exceeding the maximum payout threshold of $81 million for executive bonuses, resulting in a 39% payout for this metric.Adjusted EBITDA margin for 2024 was 21% of total revenues, surpassing the maximum payout threshold of 16% for executive bonuses, also resulting in a 39% payout for this metric.The company's Total Shareholder Return (TSR) for 2024 ($160.44) significantly outperformed its updated peer group TSR ($109.19).

Summary

The 2025 Annual Meeting of Stockholders will be held virtually on August 20, 2025, at 9:00 a.m. Pacific Time.
Key proposals for the Annual Meeting include the election of seven director nominees, an advisory vote on named executive officer compensation, and the ratification of Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
For the fiscal year ended December 31, 2024, revenue from continuing operations increased by 8% year-over-year to $82.3 million, up from $75.9 million in 2023.
The company achieved a positive adjusted EBITDA of $15.6 million, representing 19% of revenue from continuing operations.
Strategic divestitures of Global Cooling, Inc., Custom Biogenic Systems (CBS), and SciSafe generated approximately $74.7 million in cash during 2024, enabling a focus on proprietary cell processing products and services.
The company launched the CellSeal CryoCase product in 2024.
Executive compensation for 2024 was tied to Company Objectives, with an overall achievement of 88% of target levels; revenue and adjusted EBITDA metrics met maximum payout thresholds.
A new material weakness was incurred in 2024, despite the remediation of all previous material weaknesses from 2023.
The NetSuite MRP module on the Media product line was not fully implemented in 2024, resulting in 0% payout for this objective.
The CEO Pay Ratio for 2024 was 58:1, with CEO Roderick de Greef's total compensation at $7,046,205 and the median employee's compensation at $122,390.
Several Section 16(a) filings by executives and directors were filed late in 2024.
A new non-employee director compensation policy, including increased cash retainers and standardized RSU awards, will become effective January 1, 2026.

Sentiment

Score: 8

Explanation: The document highlights strong financial performance in 2024, with revenue growth and positive adjusted EBITDA exceeding internal targets, and significant cash generation from strategic divestitures. The company's Total Shareholder Return also significantly outperformed its peer group. While there were minor compliance issues with late SEC filings and a new material weakness, the overall strategic direction and financial health presented are very positive.

Positives

Revenue from continuing operations increased by 8% year-over-year to $82.3 million in 2024.
Achieved positive adjusted EBITDA of $15.6 million, representing a strong 19% of revenue.
Successful divestitures of Global Cooling, CBS, and SciSafe provided approximately $74.7 million in cash.
Strategic realignment to focus on high-growth bioproduction products and services for the cell and gene therapy market.
Release of the CellSeal CryoCase product expands the product portfolio.
Company achieved 88% of its overall 2024 Company Objectives, demonstrating strong operational performance.
Revenue and adjusted EBITDA metrics met maximum payout thresholds for executive bonuses, indicating performance exceeded targets.
Remediated all material weaknesses identified in 2023.

Negatives

Reported a GAAP Net loss from continuing operations of $(11,387) thousand for the fiscal year ended December 31, 2024.
Incurred one new material weakness in 2024, despite remediating prior ones, indicating ongoing internal control challenges.
The NetSuite MRP module on the Media product line was not fully implemented, resulting in no payout for this strategic objective.
Several Section 16(a) filings by executives and directors were filed late in 2024, indicating compliance lapses.

Risks

Risk of not fully remediating existing material weaknesses or incurring new ones, which could impact financial reporting integrity.
Potential for non-compliance with SEC filing requirements, as evidenced by late Section 16(a) reports by executives and directors.
Challenges in fully implementing strategic initiatives, such as the NetSuite MRP module, could hinder operational efficiencies.

Future Outlook

The company is keenly focused on continuing its progress and strengthening its current product portfolio and market exposure to optimize long-term value for customers and stockholders. Performance-based equity awards for the CEO are tied to fiscal year 2025 adjusted EBITDA targets of $19 million (50% payout), $21 million (100% payout), and $23 million or above (200% payout).

Management Comments

"We were able to successfully transition to a more streamlined, focused bioproduction products and services company servicing the cell and gene therapy market."
"This not only provided us with a significant influx of cash as of the year ended December 31, 2024, but also allows the Company to prioritize greater efficiencies in its proprietary cell processing products and services, deepen our relationships with existing biopreservation media customers, emphasize cross-selling of other cell processing products and services, and continue to optimize our long-term value to our customers and stockholders."
"We are keenly focused on continuing this progress and strengthening our current product portfolio and market exposure for the best interest of the Company and our stockholders."

Industry Context

The announcement reflects BioLife Solutions' strategic pivot to concentrate on the high-growth cell and gene therapy market through its bioproduction products and services. This aligns with a broader industry trend of specialization and investment in advanced therapies, moving away from less core or lower-margin businesses like cooling and storage, as evidenced by the recent divestitures. The company's focus on proprietary cell processing solutions positions it within a critical segment supporting the rapidly expanding cell and gene therapy ecosystem.

Comparison to Industry Standards

The company benchmarks executive compensation against a peer group of 20 bioprocessing, life sciences, and biotechnology companies, aiming for the 50th percentile for total annual compensation.
The peer group includes companies such as AngioDynamics, Codexis, Cryoport, Glaukos, MaxCyte, Mesa Laboratories, and Repligen Corporation.
BioLife Solutions' Total Shareholder Return (TSR) of $160.44 for 2024 significantly outperformed its updated peer group TSR of $109.19, indicating strong shareholder value creation relative to comparable companies.
The 2022 market-based stock units vested at 125% of target, reflecting the company's TSR performance at the 60th percentile compared to its peer group for the 2022-2023 period.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Executive Officer and Chairman of the Board	N/A (appointed from President and COO)	Roderick de Greef	October 19, 2023	Appointment to lead the company.
Chief Quality and Operations Officer	Chief Quality Officer	Karen Foster	January 2024	Expanded role.
Chief Technology Officer	Senior Technology Officer, Life Sciences	Sean Werner	November 2024	Promotion/Expanded role.
Former Chief Revenue Officer	Garrie Richardson	N/A (position terminated)	November 12, 2024	Involuntary termination in connection with the divestiture of SciSafe, Inc.
Director and Chair of Audit Committee	Joseph Schick	Cathy Coste	March 2025	Joseph Schick stepped down on August 1, 2024; Cathy Coste appointed March 2025.
Lead Independent Director	N/A	Amy DuRoss	August 2023	Appointment to lead independent director role.
Director and Member of Audit Committee	N/A	Tony Hunt	January 2025	Appointment to the Board.
Member of Compensation Committee	N/A	Tony Hunt	March 2025	Appointment to the committee.

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Board Composition	The Board presently consists of seven members, with six determined to be independent under Nasdaq listing rules, enhancing independent oversight.	N/A	Enhances independent oversight and adherence to governance standards.
Committee Structure	Established Audit, Compensation, and Governance & Nominating Committees, each operating under a written charter, providing structured oversight for key areas.	N/A	Provides structured oversight for key areas like financial reporting, executive compensation, and director nominations.
Risk Oversight	The Board oversees risk management directly and through its standing committees, which address risks inherent in their respective areas.	N/A	Ensures comprehensive monitoring and assessment of strategic and operational risks.
Code of Ethics	Adopted a Code of Business Conduct and Ethics for all employees, and an additional corporate code of ethics for the CEO, CFO, and other senior financial officers.	N/A	Promotes honest and ethical conduct and compliance with laws and regulations.
Insider Trading Policy	Adopted a formal insider trading policy designed to prevent insider trading and promote compliance with relevant laws and regulations.	N/A	Designed to promote compliance with insider trading laws and protect company reputation.
Incentive Compensation Clawback Policy	Maintained a clawback policy, effective October 2, 2023, requiring recoupment of incentive compensation if financial statements are restated due to material noncompliance.	October 2, 2023	Aligns executive incentives with accurate financial reporting and stockholder interests.
Non-Employee Director Compensation Policy	Adopted a new policy effective January 1, 2026, increasing annual cash retainers for directors and committee chairs, and standardizing annual RSU awards.	January 1, 2026	Aims to attract, retain, and reward qualified non-employee directors and further align their interests with stockholders.

Stakeholder Impact

Shareholders: Positive impact from strong financial performance (revenue growth, adjusted EBITDA, TSR outperformance), strategic focus on high-growth markets, and significant cash generation from divestitures. Enhanced corporate governance through independent board members and compensation policies.
Employees: Compensation programs are designed to attract and retain high-performing talent, offering competitive salaries, cash incentives, and equity awards, along with health benefits and 401(k) plan participation.
Customers: The strategic focus on the cell and gene therapy market aims to deepen relationships and optimize long-term value through proprietary cell processing products and services.
Management: Compensation is aligned with company performance through a mix of base salary, cash incentives, and equity awards, with severance protections in place.

Next Steps

Hold the 2025 Annual Meeting of Stockholders on August 20, 2025, to vote on director elections, executive compensation, and auditor ratification.
Continue to focus on strengthening the current product portfolio and market exposure in the bioproduction and cell and gene therapy markets.
Implement the new non-employee director compensation policy effective January 1, 2026.
File a Current Report on Form 8-K within four business days after the Annual Meeting to publish voting results.

Key Dates

Date	Description
June 2000	Roderick de Greef began serving as a director of the Company.
2001	Roderick de Greef began serving as Executive Vice President and Chief Financial Officer of Cardiac Science, Inc.
December 2003	Joydeep Goswami began serving at Invitrogen Corp.
November 2003	Roderick de Greef began serving as a director, member of the Audit Committee and chairman of the Compensation Committee of Endologix, Inc.
September 2005	Cardiac Science, Inc. went private.
July 2007	Roderick de Greef began providing strategic and financial consulting services to the Company.
January 2008	Roderick de Greef began serving Pareteum Corporation as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee.
November 2008	Roderick de Greef became chairman of the board of Cambridge Heart, Inc.
June 2009	Troy Wichterman became Senior Portfolio Analyst at Heitman.
September 2010	Todd Berard began serving as Director of Marketing at Verathon Medical.
2011	Rachel Ellingson began serving as Vice President, Corporate Strategy at St. Jude Medical, Inc.
January 2013	Troy Wichterman became Senior Financial Analyst, Acquisitions at Ventas.
May 2013	Amy DuRoss began serving as a Managing Director at GE Ventures.
November 2013	Roderick de Greef became president and sole director of Cambridge Cardiac Technologies, Inc.
July 2014	Todd Berard became Senior Director of Marketing at BioLife Solutions.
February 2015	Troy Wichterman became Financial Analyst at BioLife Solutions.
September 2015	Roderick de Greef began serving Pareteum Corporation as a director, chair of the Audit Committee and member of the Nominating and Corporate Governance Committee and Compensation Committee.
April 2016	Karen Foster appointed Vice President, Operations.
May 2016	Roderick de Greef appointed Chief Financial Officer.
June 2016	Troy Wichterman became Director of Financial Planning and Analysis at BioLife Solutions.
July 2016	Joydeep Goswami began serving as President of the Clinical Next-Generation Sequencing (NGS) and Oncology business unit of Thermo Fisher Scientific Inc.
January 1, 2018	Todd Berard's employment agreement became effective.
January 1, 2018	Karen Foster's employment agreement became effective.
April 2018	Rachel Ellingson began serving as Chief Administrative Officer and Chief Strategy Officer at Zimmer Biomet Holdings, Inc.
February 2019	Roderick de Greef began serving as a director and chairman of the Audit Committee of Indonesia Energy Corporation Limited.
October 2019	Sean Werner became President of Sexton Biotechnologies, Inc.
November 2019	Troy Wichterman appointed Vice President, Finance.
December 2019	Aby J. Mathew appointed Executive Vice President and Chief Scientific Officer.
December 2019	Todd Berard appointed Chief Commercial Officer.
December 2019	Karen Foster appointed Chief Quality Officer.
December 2019	Roderick de Greef appointed Chief Operating Officer.
February 2020	Sarah Aebersold became Senior Director, Global Human Resources & Administration.
August 2020	Cathy Coste began serving as a director and Audit Committee Chairman of Biomerica, Inc.
November 2020	Aby J. Mathew became a member of the Board of Directors of PanTHERA CryoSolutions, Inc.
December 1, 2020	Roderick de Greef's employment agreement became effective.
December 1, 2020	Aby J. Mathew's employment agreement became effective.
December 2020	Roderick de Greef began serving as a director of Sirona Medical Technologies.
January 2021	Sarah Aebersold appointed Vice President, Global Human Resources.
February 2021	Cathy Coste began serving as a director and Audit Committee Chairman of Minerva Surgical, Inc.
April 2021	Amy DuRoss appointed member of Governance and Nominating Committee and Chair of Compensation Committee.
April 2021	Rachel Ellingson appointed director and member of Compensation Committee and Audit Committee.
November 4, 2021	Troy Wichterman's employment agreement became effective.
November 2021	Troy Wichterman appointed Chief Financial Officer.
November 2021	Roderick de Greef began serving as President and Chief Operating Officer.
September 2022	Tim Moore appointed director and member of Compensation and Governance and Nominating Committees.
November 2022	Roderick de Greef began serving as a director of the Upper Connecticut Valley Hospital.
January 3, 2023	Roderick de Greef retired from President and Chief Operating Officer role.
January 2023	Roderick de Greef began serving as a director of the Board.
January 2023	Sarah Aebersold appointed Chief Human Resources Officer.
January 1, 2023	Aby J. Mathew's employment agreement amended.
January 1, 2023	Todd Berard's employment agreement amended.
January 1, 2023	Karen Foster's employment agreement amended.
February 2023	Joydeep Goswami began serving as Chief Financial Officer and Chief Strategy and Corporate Development Officer at Illumina.
June 1, 2023	Troy Wichterman's employment agreement amended.
June 2023	Cathy Coste began serving as a director and Audit Committee Chair of Renalytix plc.
August 1, 2023	Joseph Schick stepped down from his role as Director and Chair of the Audit Committee.
August 2023	Amy DuRoss appointed Lead Independent Director of the Board.
August 15, 2023	Troy Wichterman's employment agreement amended.
August 15, 2023	Aby J. Mathew's employment agreement amended.
August 15, 2023	Todd Berard's employment agreement amended.
August 15, 2023	Karen Foster's employment agreement amended.
October 2, 2023	Incentive compensation clawback policy became effective.
October 19, 2023	Roderick de Greef appointed Chief Executive Officer and Chairman of the Board.
October 19, 2023	Garrie Richardson's amended and restated employment agreement became effective.
January 2024	Karen Foster became Chief Quality and Operations Officer.
January 2, 2024	Non-employee directors were awarded 11,264 shares of RSUs.
March 8, 2024	Equity incentive compensation awards granted to NEOs.
March 13, 2024	Amy DuRoss's Section 16(a) filing filed late.
April 2024	Divestiture of Global Cooling, Inc. completed.
April 2024	Nanostring Technologies, Inc. acquired by Bruker Technologies.
April 18, 2024	Todd Berard's Section 16(a) filing filed late.
April 23, 2024	Sarah Aebersold, Todd Berard, Karen Foster, Aby J. Mathew, and Troy Wichterman's Section 16(a) filings filed late.
August 1, 2024	2024 Annual Meeting of Stockholders held.
August 2024	Atrion Corporation acquired by Nordson Corporation.
September 2024	Tony Hunt became Executive Chairman of Repligen Corporation.
September 2024	Silk Road Medical, Inc. acquired by Boston Scientific Corporation.
September 18, 2024	Sarah Aebersold, Todd Berard, Karen Foster, Aby J. Mathew, and Troy Wichterman's Section 16(a) filings filed late.
November 2024	Divestitures of Custom Biogenic Systems (CBS) and SciSafe completed.
November 2024	Sean Werner appointed Chief Technology Officer.
November 12, 2024	Garrie Richardson's employment was involuntarily terminated.
November 18, 2024	Todd Berard's salary increased.
December 19, 2024	Aby J. Mathew's Section 16(a) filing filed late.
December 31, 2024	Fiscal year ended.
January 2025	Tony J. Hunt appointed director and member of the Audit Committee.
January 2025	Joydeep Goswami became President and Chief Executive Officer of LGC Group.
February 2025	Tim Moore served as Executive Vice President, Chief Technical Operations at Allogene Therapeutics, Inc. through this month.
March 2025	Cathy Coste appointed director and Chair of the Audit Committee.
March 2025	Rachel Ellingson became Chief Strategy and Corporate Development Officer at Solventum.
March 2025	Tony Hunt appointed member of the Compensation Committee.
May 2025	Amy DuRoss began serving at Mayo Clinic as a MayoVenture Partner.
June 23, 2025	Record Date for the 2025 Annual Meeting of Stockholders.
July 8, 2025	Proxy solicitation materials were first sent to stockholders.
August 19, 2025	Internet voting for the Annual Meeting closes at 11:59 p.m. Eastern Daylight Time.
August 20, 2025	2025 Annual Meeting of Stockholders to be held at 9:00 a.m. Pacific Time.
December 31, 2025	Fiscal year end for which Grant Thornton LLP is appointed as independent registered public accounting firm.
January 1, 2026	New non-employee director compensation policy becomes effective.
March 10, 2026	Deadline for stockholder proposals to be eligible for inclusion in the proxy statement for the 2026 Annual Meeting (Rule 14a-8).
April 13, 2026	Karen Foster's stock option expiration date.
May 24, 2026	Deadline for notice of stockholder proposals for the 2026 Annual Meeting to avoid discretionary voting by proxy holders.
June 21, 2026	Deadline for notice of director nominees for the 2026 Annual Meeting under SEC Rule 14a-19(b).

Recommendation

buy

Keywords

BioLife Solutions, BLFS, SEC Filing, Proxy Statement, Annual Meeting, Corporate Governance, Executive Compensation, Financial Performance, Revenue, Adjusted EBITDA, Divestitures, Cell and Gene Therapy, Biopreservation, Bioproduction, Risk Management, Stockholder Vote, Director Election, Audit Committee, Compensation Committee, Nasdaq

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.